Citations

Clear

499 citation(s) found for "Tracy, PB".

Treatment‐responsive glycogen storage myopathy in a patient with POEMS syndrome: A new monoclonal gammopathy‐associated myopathy
Soontrapa, Pannathat , Tracy, Jennifer A., Liewluck, T , Soontrapa, Pannathat , Gonsalves, Wilson I. , Liewluck, Teerin

Mayo Clinic

European Journal of Neurology | July 31, 2023 | Volume: 30 | Issue: 10 | Pages: 3404-3406

10.1111/ene.16008 | PMID 37522432 Get It

Abstract Background Myopathies associated with monoclonal gammopathy are relatively uncommon and underrecognized, treatable myopathies, and include sporadic late onset nemaline myopathy, light chain amyloid myopathy, and a recently described vacuolar myopathy with monoclonal gammopathy and stiffness (VAMGS). Herein, we report a new subtype of monoclonal gammopathy‐associated myopathy (MGAM) in a polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) patient. Method Case report. Results A 51‐year‐old woman presented with a 6‐month history of progressive bilateral foot drop, lower limb edema, and a 15‐lb weight loss. She denied muscle stiffness. Neurologic exam showed severe distal weakness, mild proximal weakness, and length‐dependent sensory deficits. Laboratory studies revealed biclonal gammopathy (IgG kappa and IgA lambda), thrombocytosis, and elevated vascular endothelial growth factor. Creatine kinase was normal. Electrodiagnostic studies identified mixed demyelinating and axonal polyradiculoneuropathy and a superimposed proximal myopathy. Gluteus medius biopsy demonstrated scattered fibers with glycogen‐filled vacuoles, similar to VAMGS, with additional rare myofibers containing polyglucosan bodies. She was diagnosed with POEMS syndrome and concomitant glycogen storage myopathy. Next‐generation sequencing of glycogen storage and polyglucosan body myopathy‐related genes was unrevealing. Proximal weakness resolved after autologous stem cell transplant. Conclusions This patient expands a spectrum of MGAM. Recognition of this condition and other subtypes of MGAM is of utmost important because they are treatable.
Comparison of Outcomes Between Surveillance Ultrasound and Completion Lymph Node Dissection in Children and Adolescents With Sentinel Lymph Node-Positive Cutaneous Melanoma
Scoville, Steven D. , Rinehardt, Hannah , Sutthatarn, Pattamon , Abdelhafeez, Abdelhafeez H. , Tracy, Elisabeth T. , Favela, Juan , Davidson, Jacob , Wilson, Claire A. , Seemann, Natashia M. , Osman, Yasmin, Piché, Nelson , Hoang, Victoria, Polites, Stephanie F. , McKay, Katlyn G. , Correa, Hernán , Lovvorn, Harold N. , Lee, Yu M., Balagani, Akshitha, Dasgupta, Rohni, Dasgupta, Roshni , Tracy, Elisabeth T , Dasgupta, Roshni , Stanek, Joseph , Talbot, Lindsay J , Malek, Marcus M. , Leraas, Harold J. , Chen, Stephanie , Kim, Eugene S. , Lotakis, Dimitra M. , Ehrlich, Peter F. , Le, Hau D. , Petroze, Robin T. , Aldrink, Jennifer H.

Mayo Clinic

Annals of Surgery | July 24, 2023 | Volume: 279 | Issue: 3 | Pages: 536-541

10.1097/sla.0000000000006022 | PMID 37487006 Get It

Objective: To determine the impact of nodal basin ultrasound (US) surveillance versus completion lymph node dissection (CLND) in children and adolescents with sentinel lymph node (SLN) positive melanoma. Background: Treatment for children and adolescents with melanoma are extrapolated from adult trials. However, there is increasing evidence that important clinical and biological differences exist between pediatric and adult melanoma. Methods: Patients ≤18 years diagnosed with cutaneous melanoma between 2010 and 2020 from 14 pediatric hospitals were included. Data extracted included demographics, histopathology, nodal basin strategies, surveillance intervals, and survival information. Results: Of 252 patients, 90.1% (n=227) underwent SLN biopsy (SLNB), 50.9% (n=115) had at least 1 positive node. A total of 67 patients underwent CLND with 97.0% (n=65/67) performed after a positive SLNB. In contrast, 46 total patients underwent US observation of nodal basins with 78.3% (n=36/46) of these occurring after positive SLNB. Younger patients were more likely to undergo US surveillance (median age 8.5 y) than CLND (median age 11.3 y; P=0.0103). Overall, 8.9% (n=21/235) experienced disease recurrence: 6 primary, 6 nodal, and 9 distant. There was no difference in recurrence (11.1% vs 18.8%; P=0.28) or death from disease (2.2% vs 9.7%; P=0.36) for those who underwent US versus CLND, respectively. Conclusions: Children and adolescents with cutaneous melanoma frequently have nodal metastases identified by SLN. Recurrence was more common among patients with thicker primary lesions and positive SLN. No significant differences in oncologic outcomes were observed with US surveillance and CLND following the identification of a positive SLN.
Abstract 11108: Implementation of High-Sensitivity Cardiac Troponin Assays in the United States: A Report From the NCDR Chest Pain - MI Registry
McCarthy, Cian P. , Li, Shuang , Wang, Tracy Y , Raber, Inbar , Sandoval, Yader , Smilowitz, Nathaniel R. , Kontos, Michael C. , Apple, Fred S. , Daniels, Lori B. , Newby, L. Kristin , Jaffe, Allan S. , Daniels, Lori B , Wasfy, Jason H. , Pandey, Ambarish , Lemos, James A. de , Jaffe, Allan S. , Januzzi, James Louis

Mayo Clinic

Circulation | June 15, 2023 | Volume: 146 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.146.suppl_1.11108 Get It

Introduction: High-sensitivity cardiac troponin (hs-cTn) assays were first approved for use in the U.S. in 2017. They are the guideline preferred biomarker to evaluate patients with acute chest pain. Few data exist regarding implementation of hs-cTn assays in the U.S. Hypothesis: We hypothesize that use of hs-cTn assays has increased over time and that patients assessed with hs-cTn have a shorter length of stay (LOS) and similar use of cardiac testing. Methods: We examined trends in implementation of hs-cTn assays among participating hospitals in the NCDR Chest Pain MI Registry from 1/1/2019 through 9/30/2021. Excluding STEMI patients, associations between hs-cTn use, in-hospital diagnostic imaging, and patient outcomes were assessed using logistic or negative binomial regression models. Results: Among 550 participating hospitals with 251,000 patients in the registry, implementation of hs-cTn assays increased from 3.3% in Q1, 2019 to 32.6% in Q3, 2021 (P trend <0.0001; Figure ). Implementation was similar by hospital size, type, and geographic location. hs-cTn use was associated with more echocardiography among patients with NSTE-ACS (82% vs. 75%; aOR: 1.43, 95% CI, 1.19-1.73) but not in low-risk chest pain. hs-cTn use was associated with decreased odds of invasive coronary angiography in low-risk patients (3.7% vs. 4.5%; aOR: 0.73, 95% CI, 0.58-0.92) but similar use in NSTE-ACS. There was no association between hs-cTn use and non-invasive stress/CTCA testing. Among NSTE-ACS patients, hs-cTn use was not associated with PCI, CABG, or in-hospital mortality. Use of hs-cTn was associated with shorter LOS (47.6 hours vs. 48 hours; IRR: 0.96, 95% CI, 0.93-0.98). Conclusions: Although implementation of hs-cTn among U.S. hospitals is increasing, most U.S hospitals continue to use less-sensitive troponin assays. hs-cTn use was associated with shorter LOS overall, greater use of echocardiography in NSTE-ACS, and lower use of invasive angiograms in low-risk patients.
Survival outcomes in pediatric patients with metastatic Ewing sarcoma who achieve a rapid complete response of pulmonary metastases.
Huang, Lynn Y.L., Craig, Brian T. , Piché, Nelson , Lovvorn, Harold N. , Petroze, Robin T. , Rich, Barrie S. , Seemann, Natashia M. , Roach, Jonathan P. , Coakley, Brian A. , Grant, Christa N. , Bergus, Katherine , Bergus, Katherine C , Reiter, Audra J. , Talbot, Lindsay J , Aldrink, Jennifer H. , Polites, Stephanie F. , Dasgupta, Roshni , Malek, Marcus M. , Le, Hau D. , Kastenberg, Zachary J. , Tracy, Elisabeth T. , Lautz, Timothy B.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 11535-11535

10.1200/jco.2023.41.16_suppl.11535 Get It

11535 Background: Twenty-five percent of patients with Ewing Sarcoma (EWS) have metastatic disease at diagnosis, most commonly in the lungs. Our objectives were to compare overall (OS) and pulmonary disease-free survival (PDFS) between patients with metastatic EWS at diagnosis who achieve rapid complete response (RCR), defined as radiographic resolution of all pulmonary nodules at the end of induction chemotherapy, and those with residual pulmonary nodules after induction chemotherapy (non-RCR). Methods: This multi-center, retrospective cohort study included children under 20 years of age with metastatic EWS treated from 2007-2020 at 19 institutions participating in the Pediatric Surgical Oncology Research Collaborative. Chi-square tests were conducted for differences among groups, and p < 0.05 was considered significant. Kaplan-Meier curves were generated for OS and PDFS. Cox regression was performed for OS, controlling for whole lung irradiation (WLI), extrapulmonary metastases, and age. Results: Among 153 patients with metastatic EWS at diagnosis, 61 (40%) achieved RCR, and 87 (57%) did not (5 unknown). The median number of pulmonary nodules was 3.5 in the RCR vs 5 in the non-RCR groups (p = 0.02), while bilateral disease was present in 44 (72%) RCR vs 75 (86%) non-RCR patients (p = 0.03). Pulmonary relapse occurred in 58 (38%) patients, including 18 (29%) in the RCR and 36 (41%) in the non-RCR groups (p = 0.14). Factors associated with pulmonary relapse in the univariate analysis include median age [15 years (IQR: 12-17) with pulmonary relapse vs 12 years (IQR: 9-16) without (p = 0.03)] and extrapulmonary metastases at diagnosis [24 (41%) patients with pulmonary relapse vs 26 (27%) patients without pulmonary relapse (p = 0.05)]. WLI was performed in 100 patients and was not associated with a reduction in pulmonary relapse (p = 0.93). Complete surgical clearance of pulmonary disease was attempted in 29 (19%) patients, including 17 of the patients who met the criteria for RCR. On Kaplan-Meier analyses, 5-year PDFS did not significantly differ based on RCR (67%) vs. non-RCR (53%, p = 0.13), or WLI (61%) vs. no WLI (54%, p = 0.32). However, 5-year OS did vary significantly between patients with RCR and WLI (85%), RCR without WLI (55%), non-RCR with WLI (60%), and non-RCR without WLI (25%; p < 0.01). In Cox regression analysis, RCR was associated with improved OS after controlling for WLI, extrapulmonary metastases, and patient age (HR 0.51, p = 0.03). Conclusions: Patients with EWS who had pulmonary metastases at diagnosis had improved OS if they achieved RCR and received WLI, despite having no significant differences in rates of pulmonary relapse. Further research is needed to determine whether clearance of pulmonary disease achieved through surgical metastasectomy provides a comparable survival benefit and if any subsets of patients have a reduced risk of pulmonary relapse after resection.
2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure
Chung, Mina K. , Lau, Chu‐Pak, Forno, Alexander Romeno Janner Dal, Arora, Vanita , Birgersdotter‐Green, Ulrika , Cha, Yong‐Mei , Chung, Eugene H. , Cronin, Edmond M. , Curtis, Anne B. , Cygankiewicz, Iwona , Dandamudi, Gopi, Dubin, Anne M. , Ensch, Douglas P., Glotzer, Taya V. , Gold, Michael R. , Goldberger, Zachary D. , Gutiérrez, Alejandra , Guzmán, Juan C. , Indik, Julia H. , Karpawich, Peter P. , Khaykin, Yaariv , Kiehl, Erich L., Kutyifa, Valentina , Müllens, Wilfried , Parkash, Ratika , Patete, Manuel , Pathak, Rajeev K. , Perona, Carlos, Rickard, John , Schoenfeld, Mark H., Seow, Swee‐Chong , Shen, Win‐Kuang , Slotwiner, David J. , Sridhar, Arun Raghav Mahankali , Srivatsa, Uma N. , Stecker, Eric C. , Tanawuttiwat, Tanyanan , Tapias, Carlos A., Upadhyay, Gaurav A. , Vernooy, Kevin , Worsnick, Sarah Ann, Zaręba, Wojciech , Zeitler, Emily P. , Reviewers, Document, López-Cabanillas, Néstor , Ellenbogen, Kenneth A. , Hua, Wei , Ikeda, Takanori , Mackall, Judith A. , Mela, Theofanie , Racenet, Laurel Kay, Mason, Pamela K, Moore, Jeremy P. , Dubin, Anne M , Zareba, Wojciech , Pathak, Rajeev K , Ellenbogen, Kenneth A , Patton, Kristen K. , Forno, Alexander Dal , Al‐Khatib, Sana M. , Ensch, Douglas P., Gopinathannair, Rakesh , Gorodeski, Eiran Z. , Huang, Weijian , Imrey, Peter B. , Karim, Saima , Kron, Jordana , Link, Mark S. , Marine, Joseph Edward , Park, Seung‐Jung , Shoda, Morio , Singh, Jagmeet P , Tang, W.H. Wilson , Tracy, Cynthia M. , Varma, Niraj , Vijayaraman, Pugazhendhi , Reviewers, Document, Mason, Pamela Kay , McLeod, Christopher J.

Mayo Clinic

Journal of Arrhythmia | May 20, 2023 | Volume: 39 | Issue: 5 | Pages: 681-756

10.1002/joa3.12872 | PMID 37799799 Get It

AbstractCardiac physiologic pacing (CPP), encompassing cardiac resynchronization therapy (CRT) and conduction system pacing (CSP), has emerged as a pacing therapy strategy that may mitigate or prevent the development of heart failure (HF) in patients with ventricular dyssynchrony or pacing‐induced cardiomyopathy. This clinical practice guideline is intended to provide guidance on indications for CRT for HF therapy and CPP in patients with pacemaker indications or HF, patient selection, pre‐procedure evaluation and preparation, implant procedure management, follow‐up evaluation and optimization of CPP response, and use in pediatric populations. Gaps in knowledge, pointing to new directions for future research, are also identified.
Development of American College of Rheumatology Quality Measures for Systemic Lupus Erythematosus: A Modified Delphi Process With Rheumatology Informatics System for Effectiveness (RISE) Registry Data Review
Bartels, Christie M. , Jorge, April , Feldman, Candace H. , Zell, JoAnn, Bermas, Bonnie L. , Barber, Claire , Duarte‐García, Alí , Garg, Shivani , Haseley, Leah A., Jatwani, Shraddha , Johansson, Tracy, Limanni, Alex, Rodgers, Wendy, Santiago‐Casas, Yesenia, Suter, Lisa G., Ude, Jennifer, Aguirre, Alfredo , Li, Jing , Schmajuk, Gabriela , Bermas, Bonnie , Barber, Claire E H , Rovin, Brad H , Barnado, April , Aguirre, Alfredo , Li, Jing , Schmajuk, Gabriela , Yazdany, Jinoos , Duarte-García, Alí , Bartels, Christie M , Garg, Shivani , Rovin, Brad H. , Barnado, April , Ude, Jennifer, Yazdany, Jinoos

Mayo Clinic

Arthritis Care & Research | May 11, 2023 | Volume: 75 | Issue: 11 | Pages: 2295-2305

10.1002/acr.25143 | PMID 37165898 Get It

ObjectiveWe aimed to develop readily measurable digital quality measure statements for clinical care in systemic lupus erythematosus (SLE) using a multistep process guided by consensus methods.MethodsUsing a modified Delphi process, an American College of Rheumatology (ACR) workgroup of SLE experts reviewed all North American and European guidelines from 2000 to 2020 on treatment, monitoring, and phenotyping of patients with lupus. Workgroup members extracted quality constructs from guidelines, rated these by importance and feasibility, and generated evidence‐based quality measure statements. The ACR Rheumatology Informatics System for Effectiveness (RISE) Registry was queried for measurement data availability. In 3 consecutive Delphi sessions, a multidisciplinary Delphi panel voted on the importance and feasibility of each statement. Proposed measures with consensus on feasibility and importance were ranked to identify the top 3 measures.ResultsReview of guidelines and distillation of 57 quality constructs resulted in 15 quality measure statements. Among these, 5 met high consensus for importance and feasibility, including 2 on treatment and 3 on laboratory monitoring measures. The 3 highest‐ranked statements were recommended for further measure specification as SLE digital quality measures: 1) hydroxychloroquine use, 2) limiting glucocorticoid use >7.5 mg/day to <6 months, and 3) end‐organ monitoring of kidney function and urine protein excretion at least every 6 months.ConclusionThe Delphi process selected 3 quality measures for SLE care on hydroxychloroquine, glucocorticoid reduction, and kidney monitoring. Next, measures will undergo specification and validity testing in RISE and US rheumatology practices as the foundation for national implementation and use in quality improvement programs.image
Association of Smoking History With COVID-19 Infection, Hospitalization and Death in the C4R Study
Bowler, R.P., Elkind, Mitchell S, Kaplan, Ronald, Lee, J.S., Ortega, Victor E. , Ramachandran, V., Woodruff, Prescott G. , Balte, Pallavi , Allen, Norrina B. , Barr, R. Graham , Bowler, R.P., Cole, Shelley A. , Couper, David , Cushman, Mary , Demmer, Ryan T. , Doyle, Margaret F. , Howard, Virginia J. , Kanaya, Alka M , Kaplan, R., Phipatanakul, Wanda , Post, Wendy S. , Ramachandran, V., Schwartz, David A. , Tracy, Russell P. , Wenzel, Sally E. , Xanthakis, Vanessa , Oelsner, Elizabeth C.

Mayo Clinic

B14. COVID SEVERITY, OUTCOMES, AND DISPARITIES: FROM MOLECULE TO COMMUNITY | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A2752-A2752

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2752 Get It